YC-1
| Code | Size | Price |
|---|
| AG-CR1-0120-M001 | 1 mg | £30.00 |
Quantity:
| AG-CR1-0120-M005 | 5 mg | £75.00 |
Quantity:
| AG-CR1-0120-M025 | 25 mg | £270.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole
Appearance:
White to pale yellow powder.
CAS:
170632-47-0
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light.
InChi:
InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
InChiKey:
OQQVFCKUDYMWGV-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 170632-47-0. Formula: C19H16N2O2. MW: 304.4. Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator. Induces concentration-dependent increase in cGMP levels. Inhibits platelet adhesion to collagen. Thombosis inhibitor. Non-specific phosphodiesterase inhibitor. Na+ channel blocker. Anticancer compound. HIF-alpha inhibitor. Blocks angiogenesis. Tumor growth inhibitor. Apoptosis inducer. NK cell differentiation enhancer. TRAIL sensitizer.
MDL:
MFCD06407798
Molecular Formula:
C19H16N2O2
Molecular Weight:
304.4
Package Type:
Vial
Product Description:
Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator [1, 4]. Induces concentration-dependent increase in cGMP levels [1, 4]. Inhibits platelet adhesion to collagen [2, 8]. Thombosis inhibitor [3]. Non-specific phosphodiesterase inhibitor [5]. Na+ channel blocker [6, 9]. Anticancer compound [7, 8]. HIF-alpha inhibitor [7, 10]. Blocks angiogenesis. Tumor growth inhibitor [7, 10]. Apoptosis inducer [11]. NK cell differentiation enhancer [12]. TRAIL sensitizer [13].
Purity:
>98% (HPLC)
SMILES:
OCC1=CC=C(O1)C1=NN(CC2=CC=CC=C2)C2=CC=CC=C12
Solubility Chemicals:
Soluble in DMSO, methanol or dichloromethane.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84, 4226 (1994) | YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116, 1973 (1995) | YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320, 161 (1997) | Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53, 123 (1998) | BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292, 1057 (2002) | Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61, 97 (2002) | YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95, 516 (2003) | Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207, 1 (2004) (Review) | A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69, 278 (2006) | Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255, 107 (2007) | YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway: S.Y. Wu, et al.; Br. J. Pharmacol. 155, 505 (2008) | YC-1 enhances natural killer cell differentiation from hematopoietic stem cells: S. Yun, et al.; Int. Immunopharmacol. 10, 481 (2010) | Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis: D. Finlay, et al.; PLoS One 5, e13375 (2010)
Related Products
| Product Name | Product Code | Supplier | ODQ | AG-CR1-3500 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|